alexa Abstract | The use of patient group directions for Zanamivir in 2000/2001: cross-sectional survey of primary care organisations in England

Quality in Primary Care
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Paper Open Access


Background In November 2000, the National Institute for Clinical Excellence (NICE) issued guidance on the use of Zanamivir for high-risk patients with in? uenza. The Department of Health introduced patient group directions in August 2000 in order to allow primary care organisations to permit nurses and pharmacists to supply certain medications, such as emergency contraception,under deŽ ned circumstances without a general practitioner (GP) prescription.Aims To report on the implementation of patient group directions for Zanamivir, in particular their utilisation, feasibility and acceptability, and to derive recommendations for the future use of patient group directions.Design Cross-sectional postal questionnaire surveySetting All 474 primary care organisations in England in March 2001Participants Clinical governance leads Outcomes Whether a patient group direction was used or not and the reasons why; the timing of the implementation; the utilisation of patient group directions by pharmacies, practices and patients; the proportion of patients referred to their GP; the number of adverse events recorded; the cost of setting up and running patient group directionsand any speciŽ c issues which arose.Results The response rate was 338/474 (71.3%). Forty-three (12.7% of 338 respondents) reported that their organisation used a patient group direction for Zanamivir. The main reasons for not using a patient group direction for Zanamivir were: time or other resource constraints; concerns over validity and appropriateness of the NICE guidance for Zanamivir; concerns regarding thecost-e¡ectiveness of Zanamivir, and its appropriateness for a patient group direction approach. Other reasons included  ompeting priorities with other initiatives such as ? u immunisation; concerns about the appropriateness or safety of patient group directions for a new black triangle drug; lack of clinical need or demand; an absence of the necessary decision-making processes; lack of agreement between stakeholders; the use of a reasonable alternative; other practical implementation difficulties including inadequate training.Conclusions The Department of Health’s response to the workload implications of the introduction of Zanamivir was to introduce patient group directions.However they need to be in place before an epidemic and were not signiŽ cantly in place for the winter of 2000/2001. In the event of a ? u epidemic this winter, on this evidence, primary care is unlikely to cope with a high demand for fast access to Zanamivir

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Julia HippisleyCox


Innovative primary care, Primary care medicines, Advanced concepts in primary care

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version